Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27967611 | 0.82 | DPP4 (0.40) | LMNATSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13736563 | 0.79 | NOTUM (0.37) | TSHR | |
| SCHEMBL2959668 | 0.77 | SMN1; SMN2 (0.33) | LMNATSHRSMN1; SMN2 | |
| SCHEMBL815758 | 0.74 | TSHR (0.35) | TSHR | |
| SCHEMBL437235 | 0.74 | MAPT (0.39) | LMNATSHRSMN1; SMN2 | |
| SCHEMBL2961722 | 0.74 | CRHR1 (0.36) | TAAR1AOC3 | |
| SCHEMBL2972381 | 0.73 | TAAR1 (0.32) | TAAR1NPC1RAB9A | |
| SCHEMBL6555371 | 0.73 | ALDH1A1 (0.33) | LMNATSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2960387 | 0.73 | KCNH2 (0.32) | TAAR1AOC3 | |
| SCHEMBL2973635 | 0.73 | APP (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2012500216-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2318006-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 Pharmaceuticals, LLC (US) | 2011-05-11 | — | — | EP | claimed |
| WO-2010019903-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | claimed |
| US-9163046-B2 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9090527-B2 | Method for producing transition metal complex, catalyst for trimerization, method for producing 1-hexene, method for producing substituted cyclopentadiene compound (2) | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-28 | — | — | US | disclosed |
| US-8937195-B2 | Method for producing the transition metal complex, catalyst for trimerization, method for producing 1-hexene, method for producing the substituted cyclopentadiene compound (1) | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-20 | — | — | US | disclosed |
| EP-2691406-A1 | METHOD FOR PRODUCING THE TRANSITION METAL COMPLEX, CATALYST FOR TRIMERIZATION, METHOD FOR PRODUCING 1-HEXENE, METHOD FOR PRODUCING THE SUBSTITUTED CYCLOPENTADIENE COMPOUND (1) | Sumitomo Chemical Company, Limited (JP) | 2014-02-05 | — | — | EP | disclosed |
| EP-2691405-A1 | METHOD FOR PRODUCING THE TRANSITION METAL COMPLEX, CATALYST FOR TRIMERIZATION, METHOD FOR PRODUCING 1-HEXENE, METHOD FOR PRODUCING THE SUBSTITUTED CYCLOPENTADIENE COMPOUND (2) | Sumitomo Chemical Company Limited (JP) | 2014-02-05 | — | — | EP | disclosed |
| US-20140018565-A1 | METHOD FOR PRODUCING TRANSITION METAL COMPLEX, CATALYST FOR TRIMERIZATION, METHOD FOR PRODUCING 1-HEXENE, METHOD FOR PRODUCING SUBSTITUTED CYCLOPENTADIENE COMPOUND (2) | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| US-20140018564-A1 | METHOD FOR PRODUCING THE TRANSITION METAL COMPLEX, CATALYST FOR TRIMERIZATION, METHOD FOR PRODUCING 1-HEXENE, METHOD FOR PRODUCING THE SUBSTITUTED CYCLOPENTADIENE COMPOUND (1) | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| WO-2012133925-A1 | METHOD FOR PRODUCING THE TRANSITION METAL COMPLEX, CATALYST FOR TRIMERIZATION, METHOD FOR PRODUCING 1-HEXENE, METHOD FOR PRODUCING THE SUBSTITUTED CYCLOPENTADIENE COMPOUND (2) | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-04 | — | — | WO | disclosed |
| EP-1731513-A1 | PHENOXYACETIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-13 | — | — | EP | disclosed |
| US-20060160968-A1 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006065844-A2 | PROCESS FOR PRODUCING SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065809-A2 | HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-5750552-A | ANTIULCER AGENTS | ARAX CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5733922-A | Imidazole derivative, pharmaceutically acceptable salt thereof, and anti-ulcer drug including such derivative or salt | ARAX CO., LTD. (JP) | 1998-03-31 | — | — | US | disclosed |
| EP-0736527-A1 | Imadazoline derivative, possible tautomer thereof, process of manufacturing therefor, and vulnerary including such derivative or tautomer | ARAX CO., LTD. (JP) | 1996-10-09 | — | — | EP | disclosed |
| EP-0728747-A1 | Imidazole derivative, pharmaceutically acceptable salt thereof, process of manufacture therefor, and anti-ulcer drug including such derivative or salt | ARAX CO., LTD. (JP) | 1996-08-28 | — | — | EP | disclosed |
| US-4256458-A | DIMERIC PYRIDINIUM DYES | BASF AKTIENGESELLSCHAFT (DE) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160968-A1 | Process for producing substituted metallocene compounds for olefin polymerization | OSBP, OSBPL3, OSBP2 | LMNA 1009/4885TSHR 4116/4885TAAR1 2917/4885 |
| US-20140018565-A1 | METHOD FOR PRODUCING TRANSITION METAL COMPLEX, CATALYST FOR TRIMERIZATION, METHOD FOR PRODUCING 1-HEXENE, METHOD FOR PRODUCING SUBSTITUTED CYCLOPENTADIENE COMPOUND (2) | CPN1, CNOT9, CPNE4 | LMNA 3587/4885TSHR 261/4885TAAR1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.